Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 3Phase 1 2

Status

Unknown 4Completed 4Recruiting 2Active not recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1

Conditions

Pancreatic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Esophageal Cancer 1

Interventions

Cisplatin 270Oxaliplatin 195Carboplatin 191Capecitabine 184Docetaxel 178apatinib 164Paclitaxel 163Bevacizumab 159Gemcitabine 156Radiotherapy 147camrelizumab 146Fluorouracil 144Cyclophosphamide 126Irinotecan 120Drug Therapy 120sintilimab 108Etoposide 99anlotinib 90S 1 (combination) 89pembrolizumab 86Leucovorin 86toripalimab 78Pemetrexed 78Doxorubicin 77tislelizumab 76Dexamethasone 71Trastuzumab 65Neoadjuvant Therapy 65Rituximab 62Cetuximab 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Combined Modality Therapy × Clear all
NCT05174156 2022-07-14

Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2 Unknown
50 enrolled
Gastrointestinal

Advanced Esophageal Cancer

NCT04718701 2021-08-16

ATNPA

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
53 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04846452 2021-08-12

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04413734 2020-06-04

Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma

Zhejiang University

Phase 2 Unknown
120 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡